Clinical Study to Test Safety of a Virus Therapy in Children and Young Adults with Recurrent or Refractory Solid Tumors (Excluding Brain Tumors)
Family Friendly Version- Conditions:
Adult Studies,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neuroblastoma,
Cancer - Neurofibromatosis Tumors,
Cancer - Retinoblastoma,
Vaccines
- Gender:
Female,
Male
Cincinnati Children’s Hospital Medical Center is conducting a research study, sometimes known as a clinical trial or clinical study, to test how safe and well tolerated the study drug is in children and young adults with certain cancers. Researchers want to see what effects - good or bad - the stud...
More
ADVL0912: A Phase I/II study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in children with Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma- Conditions:
Cancer - Brain and Spinal Tumors,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neuroblastoma,
Cancer - Retinoblastoma,
Medications
- Gender:
Female,
Male
This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. ...
More
131-I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
Provide palliative therapy with MIBG for patients with advanced neuroblastoma Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma ...
More
NANT 99-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Recurrent High-Risk Neuroblastoma (A Phase I Study)- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
1. Determine the maximum tolerated dose of melphalan when combined with buthionine sulfoximine and followed by autologous bone marrow or peripheral blood stem cell support in children with recurrent high-risk neuroblastoma. 2. Assess the toxic effects of this regimen in these patients. 3. Determine...
More
NANT 2004-03: A Phase I Study of Intravenous (Emulsion) Fenretinide in Children with Recurrent or Resistant Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma. ...
More
NANT 2004-04: Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
The primary goals of this research study are: To determine the maximum tolerated dose of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™LXS) Oral Powder (4-HPR/LXS oral powder) given orally, BID, for seven consecutive days every three weeks, in patients with recurrent and/or resistant neuroblastoma. To...
More
NANT 2007-02: Bevacizumab, Cyclophosphamide, and Zoledronic Acid in Treating Patients with Recurrent or Refractory High-Risk Neuroblastoma- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects of giving bevacizumab together with cyclophosphamide and zoledronic acid in treating patients with recurrent or refractory high-risk neuroblastoma....
More
NANT 2007-03: Vorinostat With 131I-MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma....
More
NANT 2008-02: Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. ...
More
ANBL1021: Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients with Relapsed or Refractory Neuroblastoma- Conditions:
Cancer - Neuroblastoma
- Gender:
Female,
Male
This phase II trial is studying how well biological therapy works when given together with sargramostim and isotretinoin in treating patients with relapsed or refractory neuroblastoma....
More
